Search Results

BerGenBio ASA, a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced financial results for the quarter ended March 31, 2024, and provided a business update.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that it has entered into a clinical trial agreement with the Mays Cancer Center at The University of Texas Health Science Center at San Antonio and Swedish Orphan Biovitrum AB, a specialized international biopharmaceutical company.

BerGenBio ASA announced financial results for the quarter ended September 30, 2023, and provided a business update.

BerGenBio ASA (OSE: BGBIO) announced today it has initiated the Phase 2a portion of the BGBC016 clinical study of its selective AXL inhibitor bemcentinib in combination with standard of care therapy in first-line Non Small Cell Lung Cancer (NSCLC) patients harboring a STK11 mutation (STK11m).

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Dr. Mirella Spalluto of the University of Southampton today presented “Investigating the effects of AXL inhibition during respiratory viral infections” during the 6th Forum on Respiratory Infections in Glasgow, Scotland.

BerGenBio ASA today announced that a poster highlighting data from pre-planned biomarker analyses in second line Non-Small Cell Lung Cancer (NSCLC) patients treated with bemcentinib will be presented at the Society for Immunotherapy for Cancer (SITC) meeting being held on November 1-5, 2023 in San Diego, California.

BerGenBio ASA announced that a poster presentation detailing additional data from a Phase II trial of bemcentinib in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® in second line Non-Small Cell Lung Cancer patients was presented on November 4th at the 2023 Society of Immunotherapy of Cancer Annual Meeting.

BerGenBio ASA announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists Annual Meeting 2023, to be held October 20-24 in Madrid.

BerGenBio ASA announced that the full results of its Phase 2 BGBC008 study of bemcentinib and pembrolizumab in second line Non-Small Cell Lung Cancer were presented during the European Society of Clinical Oncologists Annual Meeting 2023.

BerGenBio ASA announced that additional clinical data of bemcentinib in combination with chemotherapy and with immunotherapy in Non-Small Cell Lung Cancer have been recently published and accepted for presentation at two upcoming international oncology conferences.